Absolute Software Receives Outperform Rating from Scotiabank
's stock had its "outperform" rating reiterated by research analysts at Scotiabank in a report released on Friday.
Thu Jul 24, 2014
Sanofi Drugs Sale Said to Draw Blackstone, KKR Interest
Sanofi 's $8.5 billion portfolio of older, off-patent drugs has drawn interest from private-equity firms KKR & Co., Blackstone Group and TPG Capital, people with knowledge of the matter said.
Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And...
Upon closing, Abbott will receive 105 million shares of the combined company worth approximately , representing an approximately 21% ownership stake.
Wed Jul 23, 2014
Trademark Application for 'Starlims Fusion' Filed by Abbott Laboratories
The serial number for this application is 85323171. As submitted by the applicant, this trademark application relates to the following goods and services: Software programs specifically for use in research and diagnostic laboratories, in particular to enable data interfacing between laboratory instruments and apparatus and laboratory information ... (more)
Tue Jul 22, 2014
Dold, Schneider call for government action on corporate inversions
With some of the area's largest corporations considering taking their headquarters to foreign soil, both Rep. Brad Schneider and his challenger, former Rep. Robert Dold , want to see government action.
Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories,...
Research and Markets has announced the addition of the "Global IVD Market 2014-2018" report to their offering.
Mon Jul 21, 2014
Will These EPS Estimate Cuts Hurt Abbott Laboratories (ABT) Stock Today?
The analyst firm lowered its EPS estimates for 2015 through 2018 by 7% to 10%. The firm now expects earnings of $2.66 a share in 2015, down from previous estimates of $2.87 a share for the year.
AbbVie Gets Its 'Tax Break' In Shire
The pharmaceutical industry has constantly provided us with news of gigantic mergers lately.
Fri Jul 18, 2014
Will Congress Scuttle the AbbVie-Shire Merger?
AbbVie's $54 billion proposal to acquire Irish drug maker Shire would mark the largest tax inversion ever, as a growing number of U.S. companies pursue lower rates overseas.
The Glittering Eye
What Kind of Jobs Do They Want?
Miles White, CEO of Chicago-based Abbott Laboratories, explains corporate inversion , companies' changing of national jurisdictions, frequently seeking tax relief: First, inversion is legal.
Abbott Raises Full Year Earnings Guidance On Strong Q2 Results
Healthcare giant Abbott Laboratories reported a strong set of second quarter 2014 results on Wednesday, July 16. The company's operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts' estimates of $5.52 billion compiled by Thomson Reuters.
Thu Jul 17, 2014
Markets Sell-Off After Malaysian Airline Crash In Ukraine
U.S. stocks sold off after news reports began to surface that a Malaysian Airlines jet has crashed in Ukraine.
Abbott Laboratories Given Outperform Rating at Raymond James
's stock had its "outperform" rating reiterated by Raymond James in a research note issued on Thursday.
Abbott making 'progress' repairing Fonterra botulism scare damage
Abbott Laboratories' CEO believes the company has "recovered about as well" as it could have in the year since the Fonterra WPC botulism scare that led it to recall infant formula in China, Vietnam, and Saudi Arabia.
Absolute Manage 6.5 also includes Integration with Samsung KNOX Workspace
Organizations now have the ability to secure and manage employee-owned devices beyond the traditional form factors of smartphones and tablets-all from a single console.
Wall Street Journal
Sanofi Looking At Options for Older Drug Lines
French drug maker Sanofi SA has held talks with private-equity firms and rivals including Abbott Laboratories over a potential sale of a set of older drugs valued at 6.3 billion euros , according to a Sanofi document reviewed by The Wall Street Journal.
Wed Jul 16, 2014
Investor's Business Daily
Abbott, St. Jude Top Views, But Stocks Under Pressure
Medical product giants St. Jude Medical and Abbott Laboratories both beat analysts' Q2 expectations and raised their guidance Wednesday, but their shares had a bumpy ride on the market amid a fresh attack on drug-industry mergers.
The Washington Post
Abbott's Asset Sale Provides Ammunition for Perrigo: Real M&A
Free from an underperforming unit, Abbott Laboratories is positioned to go after potential targets from Insulet Corp. to Perrigo Co.
Abbott Laboratories' (ABT) CEO, Miles White on Q2 2014 Results - Earnings Call Transcript
Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2014 Earnings conference call.